Współczesna Onkologia

Full text

2/2026 vol. 30
Original paper

Fibroblast growth factor receptor 1 status discordance between primary breast tumours and lymph node metastases is associated with peripheral blood circulating tumour cell burden

Marcin Braun 1
,
Jakub Czerwiński 1
,
Julia Richert 2
,
Julia Sołek 1
,
Dominik Paprocki 1
,
Tomasz Labuk 1
,
Michał Maj 3
,
Cecilia Analia Panek 3
,
Dominika Piasecka 4
,
Joanna Zofia Chrobak-Bień 5
,
Dariusz Nejc 6
,
Agnieszka Wanda Piastowska-Ciesielska 3
,
Radzisław Kordek 1
,
Natalia Bednarz-Knoll 2
,
Rafal Sadej 4
,
Hanna Romanska 1

  1. Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland

  2. Laboratory of Translational Oncology, Medical University of Gdansk, Gdansk, Poland

  3. BRaIn Laboratories, Medical University of Lodz, Lodz, Poland

  4. Laboratory of Enzymology and Molecular Oncology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland

  5. Department of Conservative Nursing, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland

  6. Department of Surgical Oncology, Central Teaching Hospital of the Medical University of Lodz, Lodz, Poland

Contemp Oncol (Pozn) 2026; 30 (2): 117–125

DOI: https://doi.org/10.5114/wo.2026.163812
Data publikacji online: 2026/08/17
Article file
Fibroblast growth.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Piasecka D, Braun M, Kitowska K, Mieczkowski K, Kordek R, Sadej R, et al. FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer. J Exp Clin Cancer Res 2019; 38: 230.
  2. Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Thera 2020; 5: 181.
  3. Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2019; 16: 105-22.
  4. Alba-Bernal A, Lavado-Valenzuela R, Domínguez-Recio ME, Jiménez- Rodriguez B, Queipo-Ortuño MI, Alba E, et al. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine 2020; 62: 103100.
  5. Braun M, Markiewicz A, Kordek R, Sadej R, Romanska H. Profiling of invasive breast carcinoma circulating tumour cells-are we ready for the ‘liquid’ revolution? Cancers (Basel) 2019; 11: 143.
  6. Gu X, Wei S, Lv X. Circulating tumor cells: from new biological insights to clinical practice. Signal Transduct Target Ther 2024; 9: 226.
  7. Ring A, Nguyen-Sträuli BD, Wicki A, Aceto N. Biology, vulnerabilities and clinical applications of circulating tumour cells. Nat Rev Cancer 2023; 23: 95-111.
  8. Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 WHO classification of tumours of the breast. Histopathology 2020; 77: 181-185.
  9. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021; 32: 1475-1495.
  10. Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024; 35: 159-182.
  11. Muchlińska A, Wenta R, Ścińska W, Markiewicz A, Suchodolska G, Senkus E, et al. Improved characterization of circulating tumor cells and cancer-associated fibroblasts in one-tube assay in breast cancer patients using imaging flow cytometry. Cancers (Basel) 2023; 15: 4169.
  12. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 2017; 17: 318-332.
  13. Tuokkola JE, Schwertfeger KL. Breast cancer progression by the FGF/FGFR axis: a metabolic perspective. J Mammary Gland Biol Neoplasia 2025; 31: 2.
  14. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011; 13: 227.
  15. Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget 2016; 7: 86011-86025.
  16. Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, et al. Phenotypic plasticity in circulating tumor cells is associated with poor response to therapy in metastatic breast cancer patients. Cancers 2023; 15: 1616.
  17. Würth R, Donato E, Michel LL, Saini M, Becker L, Cheytan T, et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling. Nat Cancer 2025; 6: 67-85.
  18. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst 2018; 110: 560-567.
  19. Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 2016; 22: 2583-2593.
  20. Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga JY, et al. Circulating tumor cells in early breast cancer. JNCI Cancer Spectr 2019; 3: pkz026.
  21. Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM, et al. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg 2016; 223: 20-29.
  22. Serrano MJ, Rovira PS, Martínez-Zubiaurre I, Rodriguez MD, Fernández M, Lorente JA. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med 2012; 4: 43-48.
  23. Ding M, Li M, Liu Q, Xu L. Biomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis. J Cancer Res Clin Oncol 2024; 150: 297.
  24. Marletta S, Giorlandino A, Cavallo E, Dello Spedale Venti M, Leone G, Tranchina MG, et al. Discordance of biomarker expression profile between primary breast cancer and synchronous axillary lymph node metastasis in preoperative core needle biopsy. Diagnostics (Basel) 2024; 14: 259.
  25. Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, et al. Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer 2015; 15: 307-312.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications